Pancreatic cancer vaccine trial offers ‘encouraging’ results, ‘positive outlook for the future’

  • 📰 FOX29philly
  • ⏱ Reading Time:
  • 59 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 27%
  • Publisher: 51%

Law Law Headlines News

Law Law Latest News,Law Law Headlines

The vaccine successfully stimulated an immune response in half of the treated patients, resulting in no cancer relapse after 18 months.

Compression And Constriction Of The Duodenum By A Carcinoma Of The Pancreatic Head. Abdominal X Ray In Front View.

"So the question was, what's different about these survivors compared to all other patients? And can we use this knowledge to transform this into new therapies that we could then apply to the other pancreatic cancer patients in an effort to maybe make them into long-term survivors?" Balachandran explained.

"I think the findings are encouraging that we can perhaps use more RNA vaccines that are personalized to treat pancreatic cancer and possibly other cancers," Balachandran continued. Earlier this month, a panel of experts at the FDA recommended Lynparza after a study found that pancreatic cancer patients who were treated with the drug could go nearly twice as long without their cancer worsening than those taking a placebo.

In patients who did not appear to respond to the vaccine, their cancers had come back on-average approximately 13 months after surgery. Pancreatic cancer: What you should know about the disease that led to Jerry Springer's death"All we have is a very interesting correlation, that we are now looking forward to testing in more pancreatic cancer patients as a next step," he added.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 570. in LAW

Law Law Latest News, Law Law Headlines